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Abstract  
 
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by a combination of 
autonomic failure, cerebellar ataxia and parkinsonism. Laryngeal stridor is an additional feature for 
MSA diagnosis, showing a high diagnostic positive predictive value. Stridor might be implicated in 
sudden death during sleep in MSA and its early occurrence might contribute to shorten survival, 
however a consensus definition of stridor in MSA is lacking and disagreement persists about its 
diagnosis, prognosis and treatment. An International Consensus Conference among experts with 
methodological support was convened in Bologna in 2017 to define stridor in MSA and to reach 
consensus statements for the diagnosis, prognosis and treatment. Stridor was defined as a strained, 
high-pitched, harsh respiratory sound, mainly inspiratory, occurring only during sleep or during 
both sleep and wakefulness, and caused by laryngeal dysfunction leading to narrowing of the glottis 
rimae. According to the consensus, stridor may be recognized clinically by the physician if present 
at time of examination, with the help of a witness, or by listening to an audio recording. 
Laryngoscopy is suggested to exclude mechanical lesions or functional vocal cord abnormalities 
related to different neurological conditions. If the suspicion of stridor needs confirmation drug-
induced sleep endoscopy or video-polysomnography may be useful. The impact of stridor on 
survival and quality of life remains uncertain. Continuous positive airway pressure and 
tracheostomy are both suggested as symptomatic treatment of stridor, but whether they improve 
survival is uncertain. Several research gaps emerged involving diagnosis, prognosis and treatment. 
Unmet needs for research were provided. 
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Introduction  
 
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a 
variable combination of autonomic failure, cerebellar ataxia and parkinsonian features, typically 
poorly responsive to levodopa. The diagnostic criteria define three degrees of certainty for 
diagnosis, possible, probable and definite, and two phenotypes, parkinsonian (MSA-P) and 
cerebellar (MSA-C), according to the predominant feature at the time of evaluation1-2. Causes of 
death in MSA commonly include bronchopneumonia, urosepsis or sudden death that often occurs 
during sleep2. 
Several sleep-related breathing disorders, including stridor, central and obstructive sleep apnea, 
frequently occur in MSA3-4. Stridor has been included in the diagnostic criteria as additional feature 
for the diagnosis of possible MSA, showing a high diagnostic positive predictive value5-7. A recent 
study has suggested that early stridor onset is an independent risk factor for shorter survival8, 
however its prognostic role remains controversial9-11. This may be a consequence of the distinct 
design, population characteristics and MSA diagnostic certainty (clinical vs. autopsy-based) across 
studies. Further, the lack of a universal definition for stridor as well as a gold standard for its 
diagnostic assessment may explain result heterogeneity. 
Two main options have been suggested for treating stridor: tracheostomy or continuous positive 
airway pressure (CPAP)5. Tracheostomy is currently preferred in the advanced disease stage for 
severe stridor and in case of stridor during wakefulness with immobile vocal cords on 
laryngoscopy5. CPAP as a non-invasive therapy can be used for mild and moderate intensity stridor 
occurring during sleep and related obstructive apneas. However, guidelines for stridor management 
are lacking and only a few studies have assessed the role of stridor treatment on survival8,12-14. The 
“Istituto di Ricovero e Cura a Carattere Scientifico delle Scienze Neurologiche di Bologna” 
(IRCCS-ISNB) promoted an International Consensus Conference among experts in the field with 
methodological support, convened in Bologna, Italy, on October 6th-7th 2017. The aims of the 
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conference were to: (1) determine criteria for the diagnosis of stridor and consequently define 
stridor in MSA, (2) define the prognostic value of stridor on MSA survival, (3) suggest therapeutic 
options for stridor, and (4) provide statements for future research after systematically reviewing 
evidence and identifying unmet needs for clinical practice and research grey zones. 
 
Methods 
The method was inspired by the US National Institutes of Health Consensus Development Program 
(http://consensus.nih.gov)15 and adapted from the Methodological Handbook of the Italian National 
Guideline System16. The consensus conference method is recommended for addressing important 
clinical questions in the face of limited good quality evidence. The main outcome, a consensus 
statement, represents the collective opinions of an expert panel, derived from systematic review and 
discussion of available evidence (http://www.chestnet.org/Guidelines-and-Resources/About-
CHEST-Guidelines/Guideline-Development)17. The organizer of the Bologna Consensus 
Conference was the IRCCS-ISNB, Italy. Planning and execution of the project was carried out in 
four phases: (1) assignment, (2) scoping, (3) assessment, and (4) the consensus conference itself.  
All activities, from conception to realization, were completed between February and October 2017. 
During the same period, a parallel project on dysphagia in patients with MSA was performed. 
In (1) the assignment phase, the entities and their roles were defined and participants were 
nominated and invited. Four entities were appointed: 1) the Scientific Committee (six members) 
planned and organized the whole project, nominated Consensus Development Panel and 
Workgroup members, chose the questions to be answered by the Workgroup; 2) the Technical 
Committee (two members) established methods and rules of the Consensus Conference, assisted 
with defining questions, performed the systematic review with evidence mapping; 3) one 
Workgroup of experts (eight members) focused on stridor, synthesized and integrated information 
from the systematic review before the consensus conference, provided shared answers to the 
proposed questions, and presented their findings during the Consensus Conference, including 
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research gaps and a proposal for future research; 4) the Consensus Development Panel (eight 
members) chaired the Consensus Conference, established presentation procedures, and provided 
final statements. 
In (2) the scoping phase, the scope and the protocol for the systematic review (registered on 
PROSPERO database, PROSPERO 2018 CRD42018079084, available from: 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018079084; last access 
September 29, 2018)18 and the protocol for the conference were defined. The Scientific Committee 
identified the topics and together with the Technical Committee formulated the questions to be 
addressed. The questions were framed according to the PICO model 
(https://www.cebm.net/2014/06/asking-focused-questions/)19. 
In (3) the assessment phase, the Technical Committees carried out a systematic review with 
evidence mapping, to assess the state-of-knowledge on stridor in MSA. The systematic review was 
performed following accepted criteria for the good conduct and reporting of systematic reviews18 
and reported according to PRISMA guidelines20. The descriptive map of available research 
evidence was performed by adapting the methodology reported by the Global Evidence Mapping 
Initiative21 which involved detailed coding of included studies and in-depth syntheses of the 
available research. Studies eligible for inclusion were published studies of any kind of design 
reporting original data on subjects with MSA suffering from stridor during sleep, dealing with 
diagnosis, prognosis, and/or treatment. Studies published in abstract form, narrative review or 
concept papers were excluded. Published studies were identified from the National Library of 
Medicine's MEDLINE database, Elsevier's EMBASE database, The Cochrane Central Register of 
Controlled Trials by means of specific search strategies, using a combination of exploded MeSH 
terms and free text combing the concepts of stridor in sleep and MSA (see protocol on PROSPERO 
for details: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018079084). 
Reference lists of identified articles were reviewed to find additional references. All abstracts or full 
papers without electronic abstracts were reviewed independently by two reviewers to identify 
 7 
potentially relevant studies. Each study was classified according to various descriptors, including 
topic domain, sample size, design, presence of diagnostic criteria of the stridor, and level of 
evidence according to the Classification of Evidence Schemes of the Clinical Practice Guideline 
Process Manual of the American Academy of Neurology (2011)22. Briefly, each study was graded 
according to its risk of bias from Class I (highest quality) to Class IV (lowest quality). Risk of bias 
was judged by assessing specific quality elements (i.e., study design, patient spectrum, data 
collection, masking) for each clinical topic (diagnostic accuracy, prognostic accuracy, therapeutic). 
Disagreement between the two reviewers was resolved by discussion. 
The Technical Committee then sent to the Workgroup experts a detailed summary of the systematic 
review with evidence mapping, the questions, and the abstracts of the most prominent studies, 
classified by topic and quality. The workgroup produced draft answers to be discussed during the 
Consensus Conference. 
The Consensus Conference (4) was held over two days (October the 6th and 7th, 2017) in Bologna. 
On the first day, the Consensus Development Panel established the rules for the open discussion 
meetings, appraised the state-of-knowledge on stridor in MSA and the preliminary answers 
provided by experts, and proposed future strategies for the publication of the consensus statements. 
During a contemporaneous closed meeting, the experts independently discussed and reached final 
answers to the questions assigned to them. Finally, an open discussion was held in which experts 
presented their findings and all participants debated openly to reach consensus regarding each topic 
and the need for further research. On the second day, the Consensus Development Panel drafted a 
summary of the findings in a closed session. The chairperson then reported the findings in an open 
session that included the consensus conference participants as well as other members of the 
scientific community and officials from the organizing institution. Finally, experts gave a 
presentation on needs for future research. 
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Results 
Systematic review with evidence mapping 
The literature search was performed in July 2017, and retrieved 212 citations after duplicate 
removal (Figure 1). Each retrieved article was screened to assess potential relevance, and 53 were 
reviewed from the full text for inclusion. A total of 42 studies finally met the prespecified inclusion 
criteria and 34 were used as basis for the statements. The majority of studies on diagnosis and 
treatment were of class IV quality; those on prognosis of class III (Tables 1-4). Most studies on 
diagnosis and treatment included fewer than 10 patients, and were case series or case reports as 
design. The cohort design was used in the majority of prognosis studies. 
 
Diagnosis of stridor  
Stridor is a respiratory disturbance that in MSA typically occurs during sleep and might develop at 
any time point in the disease process. According to clinical and clinico-pathological studies, stridor 
prevalence in MSA ranges from 12-42%8-12,23-25, and is similar in MSA-C and MSA-P8-9,11-12. In 
two studies, 4%-5.2% of patients presented stridor as an initial manifestation of MSA8,26.  
The clinical diagnosis of stridor remains challenging. The presence of a nighttime witness is 
typically necessary to suspect stridor since patients may be unaware of it. A high-pitched sound or 
heavy snoring are the symptoms frequently reported in patients who eventually turn out to have 
stridor, illustrating the problem of the differential diagnosis with snoring and obstructive sleep 
apnea syndrome, which are two other frequent sleep-related breathing disorders in MSA3-4,10,24,27-29.  
The term “peculiar snoring” was initially used to describe the distinctive noise occurring in MSA 
due to vibration of the vocal folds in inspiration, with a fundamental acoustic frequency of 260-330 
Hz, different from that of ordinary soft palate snoring30. Subsequently, only a single study has 
analyzed the acoustic features of stridor, in 22 MSA patients, by means of the Multi-Dimensional 
Voice Program31. This study showed that stridor can be decomposed into rhythmic and 
semirhythmic waveforms. In both cases, it is comprised of formats and harmonics, whose presence 
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suggests an origin in the vocal cords. In contrast, the sound analysis of snoring that was available 
for 18 of these patients, revealed an irregular shaped sound with no formats and harmonics. 
Studies with video-polysomnography (VPSG), which include audio recording and concurrent 
evaluation of vocal cord motion by fiberoptic laryngoscopy, showed that the high-pitched sound 
identified as stridor in MSA patients was associated with impaired vocal cord abduction, 
paradoxical adduction or both during inspiration and expiration, leading to narrowing of the glottis 
rimae. This indicates that inspiratory vibration of the narrowed vocal cord folds causes stridor32-38.  
In one VPSG study exploring breathing activity and electromyographic (EMG) activity of the 
respiratory muscles, stridor was accompanied by overactivation of intercostalis and diaphragmatic 
muscles. In this study, the observation of tonic and subcontinuous muscle recruitment with phasing-
out of thoracic as opposed to abdominal respiratory traces with paradoxical inward movements of 
the abdominal wall during inspiration were suggestive of paradoxical breathing37. 
Further VPSG studies showed that other sleep-related respiratory disturbances such as snoring, 
central and obstructive sleep apneas as well as breathing rate abnormalities (i.e. a pathological 
breathing rate increase during NREM and REM sleep) may occur in MSA patients with and without 
stridor12,24,33,37-39. 
Laryngoscopy during wakefulness in MSA patients with stridor, performed to exclude secondary 
causes or functional vocal cord abnormalities related to other neurological conditions, can reveal 
bilateral or unilateral impairment of vocal cord abduction of varying severity or normal vocal cord 
motility27,29,32-33,35-36,39-44. Conversely, impairment of vocal cord motility during wakefulness was 
also observed in MSA patients without stridor during sleep27. 
Studies with drug-induced sleep endoscopy (DISE) demonstrated impaired abduction or 
paradoxical adduction of the vocal cords in MSA patients with stridor who had normal vocal cord 
motility on awake laryngoscopy32-33,35-37,41-44. 
Finally, a few studies have performed EMG of laryngeal muscles during wakefulness and drug-
induced sleep. MSA patients with stridor could present normal EMG activity of adductor and 
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abductor laryngeal muscles during quiet breathing and inspiration. Alternatively, they could show a 
neurogenic pattern of muscle unit action potential analysis of these muscles associated with tonic 
activity of adductor muscles during quiet breathing and paradoxical activity during inspiration. 
During drug-induced sleep the main patterns were persistent tonic activity or paradoxical activation 
of laryngeal adductor muscles during inspiration35-38,44-46.  
 
Statements on the diagnosis of stridor 
Clinical features suggesting the presence of stridor 
Statements are based on core literature consisting of Class IV level studies10,12,24,31 and expert 
opinion. 
• Stridor is suspected when a high-pitched breathing sound is emitted by the patient during 
sleep or while awake, or when reported by caregivers.  
• Stridor is probably under-recognized since patients and caregivers may be unaware of its 
presence, especially when it occurs at night. 
• Recognition could be possible by the patient or caregiver after imitation of stridor by the 
physician (see supplementary sound track file).  
 
Home audio recording to support the diagnosis of stridor 
Statement is based on expert opinion since literature on the use of home audio recording to support 
the diagnosis of stridor (differential diagnosis of stridor from snoring) is lacking. 
• Patients and caregivers should be encouraged to audio record episodes of suspected stridor. 
 
VPSG to support the diagnosis of stridor  
Statements are based on core literature consisting of Class IV level studies10,12,24,31,33,37-39 and expert 
opinion. 
• VPSG including audio is not necessary if the physician has already diagnosed stridor. 
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• VPSG including audio may demonstrate stridor and its inspiratory nature. 
• VPSG can characterize other sleep sounds. 
  
Laryngoscopy for assessing stridor 
Statements are based on core literature consisting of Class IV level studies27,29,32-37,39-44 and expert 
opinion. 
• Laryngoscopy can exclude mechanical lesions (e.g. masses and scars) or functional vocal 
cord abnormalities related to different neurological conditions (central or peripheral 
disorders). 
• Laryngoscopy may reveal vocal cord motility impairment in MSA patients with stridor. 
• If awake laryngoscopy is normal, DISE might be considered if the suspicion of sleep-related 
stridor needs confirmation. 
 
Other investigations for assessing stridor 
Statements are based on core literature consisting of Class IV level studies35-38,44-46 and expert 
opinion. 
• There is no evidence that other investigations are useful. 
• EMG of the laryngeal muscles may show denervation or abnormal hyperactivity 
 
Conclusion on diagnostic criteria for stridor and definition of stridor in MSA  
• Stridor in MSA is a strained, high-pitched, harsh respiratory sound, mainly inspiratory, 
caused by laryngeal dysfunction leading to narrowing of the glottis rimae. It may occur only 
during sleep or it may be present both during sleep and wakefulness.  
• Stridor may be recognized clinically if present at the time of neurological examination, with 
the help of a witness, or by listening to an audio recording. 
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• Laryngoscopy is suggested to exclude mechanical lesions (e.g. masses and scars) or 
functional vocal cord abnormalities related to different neurological conditions (central or 
peripheral disorders). 
• If awake laryngoscopy is normal and the suspicion of sleep-related stridor needs 
confirmation, the following additional evaluations might be considered: a) DISE and b) 
VPSG to document the inspiratory nature of the sound, the presence of expiratory 
intercostalis activation or the presence of associated sleep breathing disorders 
 
Prognostic value of stridor 
Retrospective cohort studies have reported conflicting results on the prognostic value of stridor47. 
Seven studies did not find an association between the presence of stridor during the disease course 
and shortened survival8-9,11,14,48-50. In most of these studies, stridor was clinically suspected without 
instrumental confirmation. In contrast, one study showed shorter survival in MSA patients with 
stridor after VPSG recording, but not from disease onset10. Finally, the largest study with VPSG 
found that early onset of stridor (within three years from motor or autonomic symptom onset) was 
an independent predictor of shorter survival8. Based on an analysis with the Multi-Dimensional 
Voice Program, one study reported that acoustic features of stridor may affect survival in MSA31.  
 
Statements on the prognostic value of stridor 
Effect of stridor on survival 
Statements regarding the effect of stridor on survival in MSA are based on core literature consisting 
of Class II/III level studies8-11,14,31,48-50, a systematic review47 and expert opinion. 
• Whether stridor affects survival is uncertain. 
• Stridor within three years of motor or autonomic symptom onset may shorten survival. 
However identification of stridor onset may be difficult.  
• Whether specific features of stridor affect survival remains to be determined. 
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• Stridor during wakefulness is widely considered to reflect a more advanced stage of the 
disease than stridor occurring during sleep. 
 
Effect of stridor on well-being or health-related quality of life 
Literature on the effect of stridor on well-being or health-related quality of life is lacking. 
Statements are based on expert opinion. 
 
• Stridor can be distressing for patients and caregivers. 
• The impact on health-related quality of life remains to be determined. 
 
Treatment of stridor 
Four retrospective studies reported that the treatment of stridor improves survival8,12-14. Stridor 
treatment mainly comprised CPAP or tracheostomy10,27,29,32-33,35,39,51-52. In three studies (<15 
patients), CPAP initially eliminated stridor in almost all patients12,13,51, but the long-term 
symptomatic effect remains unknown.  
Three studies reported survival in MSA patients treated with CPAP. In one small study, CPAP had 
no effect on survival10. In another prospective cohort study, MSA patients with stridor receiving 
CPAP (n=13) had similar median survival compared to a group of MSA patients without stridor 
(n=26)12. Sudden death was reported in 2 out of 13 patients following CPAP initiation13. 
Classic tracheostomy is usually the surgical procedure of choice for stridor. This involves the 
positioning of a fenestrated cannula, maintained closed during the day to allow phonation53. 
Alternative techniques such as skin-lined tracheostomy have recently been proposed for the 
treatment of severe stridor in MSA54. Skin-lined tracheostomy offers several advantages, such as a 
greater opening of the stoma, higher stability over time, less risk of granulation tissue, and 
reversibility. Additionally, it does not require a cannula during the night and the stoma is easy to 
plug during the day.  
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Three studies focused on the role of tracheostomy on survival. In the largest retrospective study 
(n=42 with stridor), patients treated with tracheostomy had longer overall disease duration, longer 
disease duration after stridor onset and longer disease duration after treatment compared with those 
treated with CPAP8. Another study showed that tracheostomy may reduce the risk of death and of 
sudden death in MSA patients with stridor11. One study reported that two of the four patients with 
tracheostomy died one year after the sleep evaluation, while the other two were alive 1.9 and 7 
years later10. 
Single case reports have described the use of posterior cordotomy and arytenoidectomy28,43,44,55, and 
botulinum toxin relieved dystonic stridor in three of four patients one month after inoculation45.  
 
Statements on the treatment of stridor  
Treatment for symptomatic control of stridor 
Statements are based on core literature consisting of Class III/IV level studies8,10-14,27,29,32-33,35,39,49,51-
52 and expert opinion. 
• Ventilation during sleep (CPAP) can be useful in the symptomatic control of stridor. 
• Consider ventilation during sleep (CPAP) as a first-line symptomatic therapy.  
• Tracheostomy bypasses upper airway obstruction at laryngeal level and relieves distressing 
stridor. Tracheostomy is effective in the symptomatic control of stridor. 
• Persistent and severe stridor may require tracheostomy. 
 
CPAP for improving survival of patients with stridor 
Statement is based on core literature consisting of Class III/IV level studies8,10,12,13. 
• Whether CPAP improves survival in MSA patients with stridor is uncertain. 
 
Tracheostomy for improving survival of patients with stridor 
Statement is based on core literature consisting of Class III/IV level studies8,10,11. 
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• Tracheostomy might improve survival in patients with stridor. 
 
Other treatment options for stridor 
Statement is based on core literature consisting of Class IV level studies including case reports28,43-
45,55. 
• There is insufficient evidence for minimally invasive procedures and botulinum toxin 
injections for the symptomatic treatment of stridor. 
 
Research needs 
Several research gaps emerged during the consensus meeting concerning diagnosis, prognosis and 
treatment for stridor.  
One main challenge is the diagnosis of stridor. Whether the imitation of stridor by the physician 
during follow up visits is sufficient to correctly and earlier identify stridor or whether other tools, 
such as specific questionnaires or a home audio-recording, may improve diagnostic accuracy is 
unknown. This point could be of crucial importance if the negative prognostic role of early stridor 
onset is confirmed. It has also to be established when the use of VPSG is necessary for the 
diagnosis of stridor. For these reasons, a questionnaire for detecting stridor should be developed and 
its diagnostic accuracy be compared with VPSG in a multicenter prospective study. Similarly, the 
diagnostic accuracy of sound imitation by the physician or home audio-recording should be 
evaluated. A smartphone application could be developed to automatically recognize the stridor 
sound. Finally, the place of DISE for early stridor detection requires further investigation and the 
method to measure the progression of stridor over time should be standardized.  
The relationship between stridor and other breathing disorders (i.e. central apneas and breathing rate 
abnormalities), and their respective contributions to disease prognosis and survival should be 
determined through a multicenter prospective study. VPSG should be used to determine stridor and 
breathing disorders in this study. Moreover, further studies could contribute to elucidate the role on 
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survival of specific characteristic obtained from awake laryngoscopy, DISE, laryngeal EMG 
(denervation/muscle hyperactivity) and acoustic recordings. 
In addition, the contribution of stridor to patients and caregiver quality of life in unknown.  
To guide the physician for the treatment of stridor, randomized controlled trials comparing the 
efficacy of CPAP and tracheostomy for different degrees of stridor are warranted. Studies using 
laryngoscopy and/or laryngeal EMG should be conducted to identify specific characteristics that 
may predict treatment tolerance and response. Moreover, the usefulness of CPAP for severe stridor, 
technical aspects including titration, patient compliance and the timing of follow up need to be 
determined. Finally, the usefulness of bi-level PAP (BIPAP) should be compared with CPAP. 
Similarly to CPAP, interventional studies should also compare skin-lined versus conventional 
tracheostomy. 
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Figure 1: PRISMA Flow Diagram (Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. 
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 
2009; 339: b2535). Process and Result of the Systematic Search for Studies on Stridor in MSA. 
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Table 1: Descriptive features of eligible studies on stridor in MSA 
 All 
studies 
Number of 
patients = number 
of studies 
Cohort 
studies 
Case-
control 
studies 
Cross-
sectional 
studies 
Case 
series 
Case 
report 
Evidence 
Class 
Topic N N N N N N N  
Diagnosis 24 <10 pts = 14 studies 
10-19 pts = 7 
studies 
20-50 pts = 3 
studies 
 
- 2 5 10 7 All 
studies 
class IV  
Prognosis 11 <50 pts = 6 studies 
50-99 pts = 3 
studies 
> 100 pts = 2 
studies 
 
10 - - 1 - 2 class II 
8 class 
III 
1 class 
IV 
Treatment 25 <10 pts = 12 studies 
10-19 pts = 6 
studies 
20-50 pts = 7 
studies 
8 - - 10 7 3 class 
III 
22 class 
IV 
Each study is graded according to its risk of bias from class I to class IV (with I being highest and IV lowest quality). 
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TABLE 2: Studies that form the basis of the statements on diagnosis with their level of evidence 
First Author / year Design N. patients Diagnostic test Diagnostic 
criteria of 
stridor 
Level of 
Evidence 
Class 
Alfonsi 2016 cross-sectional 17 (11 with stridor) + 
40 normal controls 
EMG; polysomnography no IV 
Blumin 2002 case series 7 fiberoptic laryngoscopy no IV 
Chitose 2012 case report 1 awake and sleep-induced 
laryngoscopy 
no IV 
Hanson 1983 cross sectional 12 (9 with stridor) + 
controls 
speech analysis no IV 
Harcourt 1996 case series 18 endoscopy; 
polysomnography 
no IV 
Iranzo 2004 cross sectional 40 (14 with stridor) polysomnography no IV 
Isono 2001 case series 10 EMG under anesthesia 
and sleep 
no IV 
Isozaki 1996 case-control 7 awake and sleep-induced 
laryngoscopy 
no IV 
Koo 2016 cross-sectional 22 acoustic analysis yes IV 
Merlo 2002 case series 7 EMG pattern no IV 
Nonaka 2006 case series 5 sleep-induced 
laryngoscopy; EMG 
no IV 
Sadaoka 1996 case-control 8 polysomnography; 
esophageal pressure 
manometry /endoscopy 
yes IV 
Sadaoka 1997 case series 8 acoustic analysis of 
snoring, 
polysomnography, 
fiberscopic examination 
under sedation. 
no IV 
Shiba 2006 case report 1 EMG no IV 
Shimohata 2006 case report 1 polysomnography no IV 
Shimonata 2007 case series 21 (5 with stridor) polysomnography, 
laryngoscopy during 
wakefulness and under 
anesthesia 
no IV 
Silber 2000 cross-sectional 42 (17 with stridor) polysomnography yes IV 
Stomeo 2016 case report 1 sleep-induced endoscopy 
/sound analysis 
no IV 
Vetrugno 2004 cross-sectional 19 (8 with stridor) polysomnography; intra-
esophageal pressure 
recording in 3 patients 
yes IV 
Vetrugno 2007 case series 3 polysomnography 
including intra-
esophageal pressure 
recording; laryngoscopy; 
EMG 
no IV 
Williams 1979 case series 12 Fibre-optic laryngoscopy no IV 
 
Legend 
 
Each study was classified according to various descriptors, including topic domain, sample size, design, presence of 
diagnostic criteria of the syndrome and level of evidence according to the Classification of Evidence Schemes of the 
Clinical Practice Guideline Process Manual of the American Academy of Neurology (2011). Each study was graded 
according to its risk of bias from class I to class IV (with I highest quality and IV lowest quality). Risk of bias was 
judged by assessing specific quality elements (i.e. study design, patient spectrum, data collection, masking, etc.) for 
each clinical topic (diagnostic accuracy, prognostic accuracy, treatment). 
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TABLE 3: Studies that form the basis of the statements on prognosis with their level of evidence 
 
First Author / year Design N. patients Level of 
Evidence 
Coon 2015 cohort 685 (176 with stridor) II 
Giannini 2016 cohort 136 (42 with stridor) III 
Glasmacher 2017 systematic review 6 studies n.a. 
Koo 2016 cohort 22 III 
Krim 2007 cohort 86 (17 with stridor) II 
Lalich 2014 cohort 38 (25 with stridor) III 
Silber 2000 cohort 42 (30 with follow-up data, 11 with 
stridor) 
III 
Starhof 2016 cohort 99 (44 with stridor) II 
Tada 2007 cohort 49 (18 with stridor) III 
Yamaguchi 2003 cohort 83 (33 with stridor) III 
 
Legend 
 
Each study was classified according to various descriptors, including topic domain, sample size, design, presence of 
diagnostic criteria of the syndrome and level of evidence according to the Classification of Evidence Schemes of the 
Clinical Practice Guideline Process Manual of the American Academy of Neurology (2011). Each study was graded 
according to its risk of bias from class I to class IV (with I highest quality and IV lowest quality). Risk of bias was 
judged by assessing specific quality elements (i.e. study design, patient spectrum, data collection, masking, etc.) for 
each clinical topic (diagnostic accuracy, prognostic accuracy, treatment). 
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TABLE 4: Studies that form the basis of the statements on therapy with their level of evidence 
 
First Author / year Design N. patients Treatment Level of 
Evidence 
Blumin 2002 case series 7 CPAP: bilevel positive airway pressure; 
tracheostomy 
IV 
Chitose 2012 case report 1 CPAP; laser arytenoidectomy IV 
Ghorayeb 2005 case series 22 (15 with stridor) CPAP IV 
Giannini 2016 cohort 136 (42 with stridor; 31 
treated) 
CPAP (19 pts); tracheostomy (12 pts) III 
Harcourt 1996 case series 18 CPAP (2 pts); tracheostomy (2 pts); 
arytenoidectomy (3 pts) 
IV 
Iranzo 2000 cohort 20 (5 with stridor) CPAP IV 
Iranzo 2004 cohort 14 (with stridor) CPAP (13 pts) IV 
Isono 2001 case series 10 CPAP on laryngeal resistance and 
muscle activity (6 pts) 
IV 
Isozaki 1996 case series 7 tracheostomy IV 
Jin 2007 case series 18 tracheostomy (7 pts) IV 
Kneisley 1990 case report 1 arytenopexy; vocal cord pinning IV 
Lalich 2014 cohort 1 CPAP IV 
Mahmud 2015 case report 1 laser arytenoidectomy and posterior 
cordotomy 
IV 
Merlo 2002 case series 7 botulinum toxin (4 pts) IV 
Sadaoka 1996 case series 8 tracheostomy IV 
Silber 2000 cohort 42 (30 with follow-up 
data) 
CPAP (5 pts);  tracheostomy (4 pts)  IV 
Stomeo 2016 case report 1 subtotal arytenoidectomy IV 
Tada 2007 cohort 18 (with stridor) tracheotomy (12 pts) III 
Williams 1979 case series 12 tracheostomy (4 pts) IV 
Yamaguchi 2003 cohort 33 (with stridor; 15 
treated) 
CPAP; tracheostomy; laryngectomy  III 
 
Legend 
 
Each study was classified according to various descriptors, including topic domain, sample size, design, presence of 
diagnostic criteria of the syndrome and level of evidence according to the Classification of Evidence Schemes of the 
Clinical Practice Guideline Process Manual of the American Academy of Neurology (2011). Each study was graded 
according to its risk of bias from class I to class IV (with I highest quality and IV lowest quality). Risk of bias was 
judged by assessing specific quality elements (i.e. study design, patient spectrum, data collection, masking, etc.) for 
each clinical topic (diagnostic accuracy, prognostic accuracy, treatment). 
 
 
